Search
Fluticasone Nasal; EDS-FLU (Xhance)
Tradename: Xhance (FDA-approved April 2024)
Indications:
- treatment of allergic rhinosinusitis without nasal polyps
Mechanism of action:
- intranasal glucocorticoid
- EDS-Flu (Xhance) is a device that works by blowing into a mouthpiece as the spray is actuated
- this allows for deposition of fluticasone above the middle meatus to the ostiomeatal complex & sinus openings [1]
Notes:
- cash pric $800/month
Interactions
drug adverse effects of glucocorticoids
monitor with drug (more general terms)
General
fluticasone (Flonase, Veramyst, Flovent, Arnuity Ellipta)
nasal agent
References
- Palmer JN, Adappa ND, Chandra RK et al.
Efficacy of EDS-FLU for chronic rhinosinusitis: Two randomized controlled trials
(ReOpen1 and ReOpen2).
J Allergy Clin Immunol Pract 2024 Apr; 12:1049.
PMID: 38244014 Free article. Clinical Trial
https://www.jaci-inpractice.org/article/S2213-2198(23)01365-X/fulltext